Apoptotic effect of tolfenamic acid in KB human oral cancer cells: Possible involvement of the p38 MAPK pathway

Journal of Clinical Biochemistry and Nutrition

Volumn 47, Issue 1, 2010, Pages 74-80

  Kim, Jun Hee ^a   Jung, Ji Youn ^b   Shim, Jung Hyun ^a   Kim, Jin ^b   Choi, Kyeong Hee ^a   Shin, Ji Ae ^a   Choi, Eun Sun ^a   Lee, Syng Ook ^c   Chintharlapalli, Sudhakar ^c   Kwon, Ki Han ^d   Leem, Dae Ho ^e   Cho, Nam Pyo ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Kongju National University   (South Korea)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d Kwangju University   (South Korea)

^e Chonbuk National University Medical School and Hospital   (South Korea)

Author keywords

Apoptosis; KB human oral cancer cells; Mitochondrial membrane potential; P38 MAPK; Tolfenamic acid

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLFENAMIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL STRAIN KB; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUTH CANCER;

EID: 77955651661     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.10-02     Document Type: Article

References (27)

1. Agrawal, A. and Fentiman, I.S.: NSAIDs and breast cancer: a possible prevention and treatment strategy. Int. J. Clin. Pract., 62, 444-449, 2008.
2. Simon, L.S., Weaver, A.L., Graham, D.Y., Kivitz, A.J., Lipsky, P.E., Hubbard, R.C., Isakson, P.C., Verburg, K.M., Yu, S.S., Zhao, W.W., and Geis, G.S.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA, 282, 1921-1928, 1999.
3. Liu, C.H., Chang, S.H., Narko, K., Trifan, O.C., Wu, M.T., Smith, E., Haudenschild, C., Lane, T.F., and Hla, T.: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276, 18563-18569, 2001.
4. Abdelrahim, M., Baker, C.H., Abbruzzese, J.L., Sheikh-Hamad, D., Liu, S., Cho, S.D., Yoon, K., and Safe, S.: Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res., 67, 3286-3294, 2007.
5. Chan, G., Boyle, J.O., Yang, E.K., Zhang, F., Sacks, P.G., Shah, J.P., Edelstein, D., Soslow, R.A., Koki, A.T., Woerner, B.M., Masferrer, J.L., and Dannenberg, A.J.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59, 991-994, 1999.
6. Ferrandina, G., Legge, F., Ranelletti, F.O., Zannoni, G.F., Maggiano, N., Evangelisti, A., Mancuso, S., Scambia, G., and Lauriola, L.: Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer, 95, 801-807, 2002.
7. Khuri, F.R., Wu, H., Lee, J.J., Kemp, B.L., Lotan, R., Lippman, S.M., Feng, L., Hong, W.K., and Xu, X.C.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res., 7, 861-867, 2001.
8. Maitra, A., Ashfaq, R., Gunn, C.R., Rahman, A., Yeo, C.J., Sohn, T.A., Cameron, J.L., Hruban, R.H., and Wilentz, R.E.: Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am. J. Clin. Pathol., 118, 194-201, 2002.
9. Marrogi, A., Pass, H.I., Khan, M., Metheny-Barlow, L.J., Harris, C.C., and Gerwin, B.I.: Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res., 60, 3696-3700, 2000.
10. Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., and Kawasaki, H.: Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology, 46, 407-412, 1999.
11. Shirahama, T.: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin. Cancer Res., 6, 2424-2430, 2000.
12. Shono, T., Tofilon, P.J., Bruner, J.M., Owolabi, O., and Lang, F.F.: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res., 61, 4375-4381, 2001.
13. He, T.C., Chan, T.A., Vogelstein, B., and Kinzler, K.W.: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 99, 335-345, 1999.
14. Zhang, L., Yu, J., Park, B.H., Kinzler, K.W., and Vogelstein, B.: Role of BAX in the apoptotic response to anticancer agents. Science, 290, 989-992, 2000.
15. Eskerod, O.: Gastrointestinal tolerance studies on tolfenamic acid in humans and animals. Pharmacol Toxicol., 75 Suppl. 2, 44-48, 1994.
16. Isomäki, H., Martio, J., Kaarela, K., Kajander, A., Koota, K., Lehtinen, K., Luukkainen, R., Martio, T., Nissilä, M., Nuotio, P., and Sarna, S.: Comparison of the analgesic effect of ten nonsteroidal anti-inflammatory drugs. Br. J. Rheumatol., 23, 61-65, 1984.
17. Keinanen, S., Simila, S., and Kouvalainen, K.: Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid. Eur. J. Clin. Pharmacol., 13, 331-344, 1978.
18. Abdelrahim, M., Baker, C.H., Abbruzzese, J.L., and Safe, S.: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl. Cancer Inst., 98, 855-868, 2006.
19. Lee, S.H., Bahn, J.H., Choi, C.K., Whitlock, N.C., English, A.E., Safe, S., and Baek, S.J.: ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol. Cancer Ther., 7, 3739-3750, 2008.
20. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., and Gotoh, Y.: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 275, 90-94, 1997.
21. Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., Peng, T.I., Jones, D.P., and Wang, X.: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 275, 1129-1132, 1997.
22. Hansen, P.E.: Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol. Toxicol., 75 Suppl. 2, 81-82, 1994.
23. Van Laethem, A., Van Kelst, S., Lippens, S., Declercq, W., Vandenabeele, P., Janssens, S., Vandenheede, J.R., Garmyn, M., and Agostinis, P.: Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes. FASEB J., 18, 1946-1948, 2004.
24. Kim, B.S., Yoon, K.H., Oh, H.M., Choi, E.Y., Kim, S.W., Han, W.C., Kim, E.A., Choi, S.C., Kim, T.H., Yun, K.J., Kim, E.C., Lyou, J.H., Nah, Y.H., Chung, H.T., Cha, Y.N., and Jun, C.D.: Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Cell Immunol., 220, 96-106, 2002.
25. Park, M.T., Choi, J.A., Kim, M.J., Um, H.D., Bae, S., Kang, C.M., Cho, C.K., Kang, S., Chung, H.Y., Lee, Y.S., and Lee, S.J.: Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J. Biol. Chem., 278, 50624-50634, 2003.
26. Mandal, C., Dutta, A., Mallick, A., Chandra, S., Misra, L., Sangwan, R.S., and Mandal, C.: Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis, 13, 1450-1464, 2008.
27. Papineni, S., Chintharlapalli, S., Abdelrahim, M., Lee, S.O., Burghardt, R., Abudayyeh, A., Baker, C., Herrera, L., and Safe, S.: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis, 30, 1193-1201, 2009.